Introduction {#s1}
============

Perfluoroalkyl substances (PFASs) are synthetic chemicals manufactured since the 1950s that have been used to water- and stain proof various industrial and consumer products including clothing, carpets, food packing material, and kitchenware ([@c8]; [@c37]). PFASs are extremely resistant to biotransformation and environmental degradation. The two most commonly used PFASs, perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), have estimated biological half-lives of 3--5 y in humans ([@c21]; [@c43]). Humans are nearly ubiquitously exposed to PFASs from bioaccumulation in the food chain or contamination of food packaging material, indoor air and household environments, or drinking water ([@c50]). Production of PFOS and PFOA has been decreasing in the United States and Europe since 2000 ([@c8]), but they are still widely detectable ([@c9]; [@c12]; [@c25]). At the same time, exposures to other types of PFASs such as perfluorononanoic acid (PFNA) have found to be increasing ([@c9]; [@c25]). Newer types of fluorinated compounds used as substitutes for PFOA, such as Gen-X \[also named perfluoro-2-propoxypropanoic acid (PFPrOPrA) or hexafluoropropylene oxide--dimer acid (HFPO-DA)\], have also been recently detected in biota ([@c12]; [@c17]; [@c50]).

Thyroid hormones (THs) are critical for normal brain development of the fetus during pregnancy and in early postnatal life ([@c11]; [@c18]). The fetus begins producing its own supply of THs around the end of the first trimester, and the fetal thyroid gland may be functionally mature at approximately 18 to 20 weeks of gestation ([@c18]; [@c42]). Thus, in the first to mid-second trimester, the fetus depends largely on maternal THs ([@c11]). Recently, evidence has indicated that even subtle changes in maternal thyroid function during pregnancy may impair neurodevelopment in the child ([@c28]; [@c20]; [@c19]; [@c4]). Maternal TH levels in early gestations change during the course of pregnancy, posing challenges for the detection of anomalies of thyroid function in this early, important period of development ([@c29]).

Biological studies have demonstrated that PFASs have a rather strong ability to interfere with thyroid function, possibly by affecting enzymes in the thyroid gland or disturbing hypothalamic--pituitary--thyroid (HPT) axis responsiveness or binding to transthyretin ([@c24]; [@c39]; [@c54]; [@c57]). A previous review showed that higher levels of PFOS have been associated with higher levels of thyroid-stimulating hormone (TSH) in the second trimester of pregnancy in four epidemiological studies, but associations between other types of PFAS and THs were inconclusive ([@c7]). The majority of previous studies were smaller in size and have evaluated associations between PFASs and THs only in the second and third trimester ([@c7]). Only one study evaluated PFASs and THs in early pregnancy \[around gestational week (GW) 10\] among 732 mothers in Boston, Massachusetts, and found no associations between six types of PFAS and maternal total thyroxine (T4); however, PFOA, perfluorohexane sulfonate (PFHxS), and 2-(*N*-methyl-perfluorooctane sulfonamido) acetate (MeFOSAA) were inversely associated with the maternal free T4 (fT4) index, calculated from total T4 and level of triiodothyronine (T3) resin uptake (T3U) to estimate the circulating fT4 levels after accounting for thyroid-binding protein levels ([@c45]).

In this study, we evaluated the associations between six types of PFAS and maternal thyroid function (determined by TSH and fT4) in early pregnancy among 1,366 pregnant women enrolled in the Danish National Birth Cohort (DNBC). We also investigated whether the possible PFAS and TSH or fT4 relationships might vary by gestational week in early pregnancy.

Materials and Methods {#s2}
=====================

Study Participants {#s2.1}
------------------

The DNBC is a national pregnancy cohort study established during 1996--2002 with 100,417 pregnant women originally enrolled by their general practitioners at their first antenatal visit ([@c44]). In the present study, we analyzed data from 1,366 pregnancies in the DNBC for which both PFAS and TH levels were measured in the same maternal plasma samples all collected in the same time period (i.e., 1996--2002) at study enrollment and during GW5 to GW19 {$\text{median\  }\left\lbrack \text{interquartile\ range\  }\left( \text{IQR} \right) \right\rbrack = 8\,\left( 7 - 10 \right)\}$. Specifically, prenatal PFAS measures were generated in three subcohort studies nested within the DNBC (termed Study Samples 1, 2, and 3 according to the chronological order of the time of measure) ([@c16]; [@c35], [@c34]). TH levels were measured in two samples, with one selected about 12% random subset of the DNBC to establish TH screening reference limits in early pregnancy ([@c29]). The second-sample included mothers and children participated in the nested Lifestyle During Pregnancy Study (LDPS) cohort designed to evaluate prenatal alcohol intake and neuropsychological outcomes in children at 5 years of age ([@c3]; [@c26]).

Details of the sampling criteria and flowchart of selection for the three study samples are presented in [Figure 1](#f1){ref-type="fig"}. Briefly, Study Sample 1 measured PFOA and PFOS for 1,400 mothers selected at random from among those who completed all four baseline interviews and a 7-y follow-up questionnaire ([@c16]); among these women, 188 had TH measures available. Study Sample 2 included 545 children randomly selected at birth (boy-to-girl ratio of 4:1) as population controls for a case--cohort study ([@c36]); among these children, 97 had TH measures available. Study Sample 3 contained the majority of all samples used in this study ($N = 1,081$) from mothers and children who participated in the nested LDPS cohort at 5 years of age ([@c26]). Study Sample 3 had a higher proportion of women with alcohol intake during pregnancy due to the over-sampling strategy. Measures of 16 types of PFAS were available in Study Samples 2 and 3.

![Sample selection for the three substudy samples. Note: DNBC, Danish National Birth Cohort; LDPS, Lifestyle During Pregnancy Study; PFAS, perfluoroalkyl substance; PFDA, perfluorodecanoic acid; PFHpS, perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; TH, thyroid hormone.](ehp-127-117002-g001){#f1}

All participants provided written informed consent at the time of inclusion in the DNBC. The research protocol for this study was approved by the Danish data inspectorate (journal no. 2016-051-000001, serial no. 1343), and the institutional review boards at UCLA (16-001849) and Yale University (2000024089).

PFAS Measurements {#s2.2}
-----------------

All blood samples collected in the DNBC were sent by mail to the Statens Serum Institute in Copenhagen and stored in $- 20{^\circ}C$ or $- 80{^\circ}C$ freezers. Samples in the Study Samples 2 and 3 were analyzed at the Department of Environmental Science at Aarhus University, Denmark ([@c35]), and samples in Study Sample 1 were analyzed at the $3M$ Toxicology Laboratory (San Paul, Minnesota, USA) ([@c14]). Details about the analytic methods for PFAS measures have been described elsewhere ([@c16]; [@c35], [@c36]). Briefly, $0.1\;{mL}$ stored maternal plasma retrieved from the biobank for each participants were sorted in random order. Both laboratories employed similar analytic methods using a solid-phase extraction technique for sample extraction and purification, and liquid chromatography--tandem mass spectrometry to measure PFAS concentrations. Only PFOS and PFOA were measured in Study Sample 1 because only these two PFAS compounds could be measured in 2007. Sixteen PFASs were measured in Study Samples 2 and 3 between 2011 and 2014. For Study Samples 2 and 3, our analyses focused on six types of PFAS that were quantifiable in $> 90\%$ of all measured samples and included PFOS at 100%; PFOA, 100%; PFHxS, 98%; perfluoroheptane sulfonate (PFHpS), 96%; PFNA, 92%; and perfluorodecanoic acid (PFDA), 90% ([@c35], [@c36]). Values below the lower limit of quantitation were replaced by a multiple imputation algorithm that included all PFASs and some demographic variables ([@c35], [@c34]). Details on detection and quantitation limits for each PFAS can be found in Table S1.

Comparisons of PFAS measurements in the two laboratories have been performed previously ([@c35]). We found that the absolute PFOS and PFOA value read-outs at the $3M$ laboratory were slightly higher than at the Aarhus University laboratory, but the correlations of PFOS and PFOA concentrations measured in the same samples ($n = 21$) by the two laboratories were very high (Pearson correlation $r = 0.94$ for PFOS and $r = 0.95$ for PFOA). Pooled analyses combining PFAS measures across the study samples generated in the DNBC have been conducted ([@c6]; [@c15]; [@c41]).

Thyroid Hormone Measurements {#s2.3}
----------------------------

TSH and fT4 were measured in 2015 using the Dimension Vista® automated immunoassay (Siemens Healthcare Diagnostics) as described in detail elsewhere ([@c29]). Most of the women included in the studies did not have thyroid disease (i.e., no diagnosis or treatment) nor did they receive treatment for thyroid disease at the time of blood sampling ([@c2]). The gestational-week--specific distributions of TSH and fT4 from GW5 to GW19 in the DNBC have been described previously; TSH exhibited a U-curved trend with a nadir at GW10, and fT4 exhibited an inverted U-curved trend with a peak also at GW10 ([@c29]).

Covariates {#s2.4}
----------

Potential confounding factors were selected *a priori* according to a directed acyclic graph (see Figure S1). Our models included maternal age at delivery ($< 25$, 25--29, 30--34, $\geq 35\; y$), parity (0, 1, $> 1$), socio-occupational status (a four-level variable created based on the highest maternal or paternal education and occupation as 1 for a high-grade professional with long-term education; 2 for a medium-grade professional with medium-term education; 3 for a skilled worker or work in position that required a shorter education; and 4 for unskilled workers, unemployment, or those on financial assistance), maternal prepregnancy body mass index (BMI; $\leq 18.5$, 18.5 to $< 25$, 25 to $< 30$, $\geq 30{\,{kg}/m}^{2}$), gestational week of blood sampling measure (continuous and square transformed), maternal smoking during pregnancy (yes, no), and child's birth year ($< 2000$, $\geq 2000$). Information regarding these demographic variables were collected from maternal interveiws conducted during pregnancy. The gestational week of blood sampling was calculated using the date of sampling registered in the DNBC biobank, and the date of birth and the gestational age at birth of the child were obtained from the Danish Medical Birth Registry ([@c29]). In Denmark, gestational age is recorded based on the date of last menstrual period (on average 2 weeks before conception) in combination with ultrasound verification. We calculated the first day from the last menstrual period by subtracting the registered gestational age (in days) from the date the child was born, and then estimated the gestational week of blood sampling from the date of sampling. Gestational week of blood sampling ranged from GW5 to GW19.

Statistical Analysis {#s2.5}
--------------------

TSH and fT4 levels were first analyzed as continuous values after a natural-log transformation to address normality assumptions in linear regression models and improve model fit. We used multivariable linear regression models to estimate the relationships between ln-TSH or ln-fT4 and PFAS exposures. To increase the interpretability of the results, the coefficient for the exposure variable in this model was exponentiated and reported as the relative change (or ratio) of the geometric mean of TSH (in milli-international units per liter) and fT4 (in picomoles per liter) according to exposures. Moreover, we also calculated the percent difference using the formula $\left\lbrack {\text{exp\  }\left( \text{beta} \right) - 1} \right\rbrack \times 100\%$ to facilitate comparisons with a previous study ([@c45]). PFASs were analyzed as continuous \[per interquartile range (IQR) increase\] or categorical (quartiles with the lowest quartile as reference) variables. The IQR for each PFAS was calculated using the total sample distributions (see Table S2). All potential covariates mentioned above were also included in the model.

We conducted stratified analyses using binary categories for socio-occupational status (Levels 1 and 2 vs. Levels 3 and 4), parity (nulliparous vs. multiparous), maternal smoking (smoker vs. nonsmoker), child's birth year ($< 2000$ vs. $\geq 2000$), geographical residence (East vs. West Denmark), maternal age at birth ($< 30$ vs. $\geq 30$), and alcohol intake during pregnancy (drinker vs. nondrinker) because these factors had previously been suggested to be associated with maternal TH function in the DNBC ([@c2], [@c3]; [@c29]) and they could potentially modify the effect estimates of PFAS exposures ([@c7]; [@c33]; [@c46]). Tests of heterogeneity were also performed by assessing the *p*-value of the interaction term for each PFAS and potential modifying factors in the regression models.

Because maternal TSH or fT4 values may follow (inverted) U-shapes in early pregnancy, we included a linear and a quadratic term for the continuous gestational week variable in the models. To account for possible laboratory differences or batch effect, an indicator variable for study (1, 2, or 3) was entered for all continuous PFAS analyses ([@c6]; [@c41]), and a study sample--specific cutoff was used to generate PFAS quartiles. PFAS levels below the lower limit of quantitation and missing covariate values were replaced using a multiple imputation algorithm that included six PFAS and all of the abovementioned covariates in the model ([@c40]).

We also fitted a more flexible model to study whether the PFAS and TSH or fT4 relationships might vary by gestational week. We included interaction terms for the gestational week (continuous and square transformed) and binary exposure variables (the lowest three quartiles vs. the highest quartile) into multivariable linear regression models. We then estimated the expected TSH and fT4 values for each PFAS exposure group in each gestational week while adjusting for potential confounders using the marginal standardization form of the predictive margins ([@c55]). Considering the dimensionality of this model, all PFAS values were dichotomized as low or high. First, we compared the three lower PFAS quartiles to the highest quartile, and second, we compared only the lowest to the highest quartile. We furthermore performed analyses for binary PFAS and continuous TSH and fT4 values according to whether the samples were collected before or after GW10. GW10 was suggested as the nadir point for the dynamic changes of TSH and fT4 during early pregnancy, as previously reported for this cohort ([@c29]).

Moreover, we studied possible TH abnormalities based on the gestational-week--specific distribution of TSH and fT4 ([@c29]). Because the number of women with clinical or subclinical hyper- or hypothyroidism ([@c13]) was very small and we focused on the dynamic changes in THs by gestational week ([@c29]) rather than thyroid disease status, we used 10th and 90th percentile week--specific cutoffs to classify women as having a relatively high or low TSH or fT4 hormone status; for example, low TSH ($< 10\text{th}$), high TSH ($> 90\text{th}$), low fT4 ($< 10\text{th}$), or high fT4 ($> 90\text{th}$) status. Multinomial logistic regression models were used to estimate odds ratios (ORs) for each outcome and continuous PFAS exposures. We used normal \[10th--90th\] TH levels as the reference group to which we compared low ($< 10\text{th}$) or high ($> 90\text{th}$) TH--level groups. We also performed the multinomial logistic regression models using only Study Sample 3 or excluding 37 women who self-reported ever receiving a diagnosis of thyroid disease, including those currently having the conditions in early gestations.

In sensitivities analyses, we additionally adjusted for geographical residence (East vs. West Denmark) as a proxy variable for iodine intake. There are geographical differences in iodine intake levels due to different iodine contents in Danish groundwater ([@c30]). Moreover, we also controlled for fish intake (less than once per month, less than once per week, more than once per week) and maternal alcohol intake (yes, no) during early pregnancy. To assess the influence of co-exposure to different PFASs, we contrasted multi-pollutant models for continuous TH levels after including one PFAS at a time according to their prevalence. Our first model included only PFOS and PFOA, and we then added---one by one---PFHxS, PFNA, PFHpS, and PFDA (in this order). Analyses that co-adjusted for all six PFASs were also performed with gestational-week--specific TH values and binary PFAS exposures.

Stabilized inverse-probability-weights (IPWs) were used to account for subject selections into each of the subsamples ([@c34]; [@c41]). Briefly, the IPWs first accounted for the disproportionate infant's sex ratios in Study Sample 2 and the oversampling of alcohol drinkers in Study Sample 3. The selection criteria of Study Samples 1 and 3 conditioned on follow-up at 5 years of age in the nested LDPS cohort (among those invited, $\sim 50\%$ participated), or at 7 years of age among mothers who returned an online questionnaire (among those invited, $\sim 60\%$ participated), which could induce selection bias. Therefore, the IPWs also incorporated the modeled probabilities of follow-up using a range of baseline factors that were available for all eligible women. Some of the main predictors for participation included maternal age, parental social class, prepregnancy BMI, maternal smoking and alcohol intake during pregnancy, organic food intake during pregnancy, child's birth year, and child's birth outcome such as preterm birth and low birth weight ([@c34]; [@c41]). Robust variance estimators were used to compute 95% confidence intervals (CIs) in all weighted regression analyses. All statistical analyses were conducted using SAS (version 9.4; SAS Institute Inc.) and STATA (version 15; StataCorp LLC).

Results {#s3}
=======

[Table 1](#t1){ref-type="table"} presents the baseline demographic characteristics of the study participants (unweighted) by the study sample. The PFOS and PFOA values in Study Sample 1 were slightly higher because of laboratory difference, whereas PFAS levels in Study Samples 2 and 3 were rather comparable. A Pearson correlation matrix for the six PFASs is presented in Table S3. The gestational-week--specific distribution of maternal TSH and fT4 in all samples is presented in Table S4.

###### 

Study characteristics of the three study samples (unweighted) from the Danish National Birth Cohort.

Table 1 lists characteristics in the first column; the corresponding total number, number of participants in Sample 1, Sample 2, and Sample 3 are listed in the other columns.

  Characteristics                                                    Total               Sample 1                               Sample 2            Sample 3
  ------------------------------------------------------------------ ------------------- -------------------------------------- ------------------- -------------------
  Thyroid hormones \[GM (95% CI)\]                                                                                                                  
   TSH (mIU/L)                                                       1.13 (1.08, 1.19)   1.20 (1.06, 1.37)                      1.01 (0.86, 1.18)   1.13 (1.08, 1.19)
   fT4 (pmol/L)                                                      14.2 (14.1, 14.3)   14.6 (14.3, 14.9)                      14.9 (14.6, 15.2)   14.1 (14.0, 14.2)
  PFAS {ng/mL \[median (IQR)\]}                                                                                                                     
   PFOS                                                              29.5 (22.6--37.7)   34.2 (27.5--43.5)                      29.6 (19.3--37.0)   28.6 (22.2--36.5)
   PFOA                                                              4.52 (3.38--5.80)   5.41 (3.39--7.10)                      4.14 (2.88--5.84)   4.43 (3.34--5.62)
   PFHxS                                                             1.11 (0.83--1.39)   NA[^*a*^](#TF2){ref-type="table-fn"}   0.94 (0.58--1.23)   1.13 (0.84--1.41)
   PFNA                                                              0.45 (0.36--0.57)   NA[^*a*^](#TF2){ref-type="table-fn"}   0.42 (0.34--0.52)   0.46 (0.36--0.57)
   PFHpS                                                             0.37 (0.27--0.49)   NA[^*a*^](#TF2){ref-type="table-fn"}   0.30 (0.21--0.43)   0.38 (0.28--0.50)
   PFDA                                                              0.17 (0.13--0.22)   NA[^*a*^](#TF2){ref-type="table-fn"}   0.16 (0.11--0.24)   0.17 (0.14--0.22)
  Mother's age {y \[$n$ (%)\]}                                                                                                                      
   19--29                                                            607 (44.4)          82 (43.6)                              51 (52.6)           474 (43.9)
   30--34                                                            534 (39.1)          74 (39.4)                              34 (35.0)           426 (39.4)
   35--45                                                            225 (16.5)          32 (17.0)                              12 (12.4)           181 (16.7)
  Gestational week at time of blood collection \[mean (min, max)\]   8.3 (5, 19)         8.0 (5, 13)                            7.8 (5, 14)         8.4 (5, 19)
  Parity \[$n$ (%)\]                                                                                                                                
   0                                                                 716 (52.4)          85 (45.2)                              49 (50.5)           582 (53.8)
   1                                                                 410 (30.0)          68 (36.2)                              34 (35.1)           308 (28.5)
   $> 1$                                                             240 (17.6)          35 (18.6)                              14 (14.4)           191 (17.7)
  Parental socio-occupational status \[$n$ (%)\]                                                                                                    
   1 (the highest)                                                   491 (35.9)          61 (32.5)                              28 (28.9)           402 (37.2)
   2                                                                 450 (32.9)          59 (43.6)                              28 (28.9)           363 (33.6)
   3                                                                 388 (28.4)          62 (33.0)                              36 (37.1)           290 (26.8)
   4 (the lowest)                                                    37 (2.7)            6 (3.2)                                5 (5.2)             26 (2.4)
  Maternal smoking during early pregnancy \[$n$ (%)\]                432 (31.6)          52 (27.7)                              26 (26.8)           354 (32.8)
  Mother's prepregnancy BMI {${{kg}/m}^{2}$ \[$n$ (%)\]}                                                                                            
   $\leq 18.5$                                                       79 (5.8)            8 (4.3)                                8 (8.3)             63 (5.8)
   $18.5– < 25$                                                      923 (67.6)          113 (60.1)                             59 (60.8)           751 (69.5)
   $25– < 30$                                                        262 (19.2)          47 (25.0)                              21 (21.7)           194 (18.0)
   $\geq 30$                                                         102 (7.5)           20 (10.6)                              9 (9.3)             73 (6.8)
  Birth year {y \[$n$ (%)\]}                                                                                                                        
   $< 2000$                                                          402 (29.4)          56 (29.6)                              35 (35.7)           311 (28.8)
   $\geq 2000$                                                       966 (70.6)          133 (70.4)                             63 (64.3)           770 (71.2)
  Fish intake                                                                                                                                       
   No                                                                52 (3.8)            6 (3.2)                                5 (5.1)             41 (3.8)
   Low                                                               220 (16.1)          34 (18.0)                              18 (18.4)           168 (15.5)
   Medium                                                            673 (49.2)          95 (50.3)                              45 (45.9)           533 (49.3)
   High                                                              423 (30.9)          54 (28.6)                              30 (30.6)           339 (31.4)
  Geographical residence \[$n$ (%)\]                                                                                                                
   East                                                              484 (35.4)          53 (28.2)                              43 (44.3)           388 (35.9)
   West                                                              882 (64.6)          135 (71.8)                             54 (55.7)           693 (64.1)

Note: BMI, body mass index; CI, confidence interval; fT4, free thyroxine; GM, geometric mean; IQR, interquartile range; max, maximum; min, minimum; NA, not available; PFAS, perfluoroalkyl substance; PFDA, perfluorodecanoic acid; PFHpS, perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; Ref, reference; TSH, thyroid-stimulating hormone.

PFHxS, PFNA, PFHpS, and PFDA were not measured in Sample 1.

PFAS Exposure and Average Changes of Thyroid Hormone Levels in Early Pregnancy {#s3.1}
------------------------------------------------------------------------------

There were no apparent associations between higher PFASs in a linear model or exposure quartiles and changes in average TSH or fT4 levels in all samples ([Table 2](#t2){ref-type="table"}). These findings did not change when additionally adjusting for fish intake in pregnancy, geographical residence, and alcohol intake (see Table S5) or in models that mutually adjusted for different types of PFAS (see Table S6). There was also no evidence for effect measure modifications with any of the PFASs by strata of socio-occupational status, parity, maternal smoking, child's birth year, geographical residence, maternal age at birth, or alcohol intake during pregnancy (see Table S7).

###### 

Associations between maternal thyroid hormone levels and plasma PFAS levels (ng/mL) in all samples.

Table 2 lists PFASs in the first column; the corresponding relative percentage difference and absolute percentage difference for TSH (milli international units per liter) and fT4 (picomoles per liter) are listed in the other columns.

  PFAS                TSH (mIU/L)         fT4 (pmol/L)                                   
  ------------------- ------------------- -------------------------- ------------------- ------------------------
  PFOS                                                                                   
   Per IQR increase   1.04 (0.96, 1.14)   4.3 ($- 4.3$, 13.8)        1.00 (0.99, 1.02)   0.4 ($- 1.0$, 1.8)
    Quartile 1        Ref                 Ref                        Ref                 Ref
    Quartile 2        0.86 (0.69, 1.06)   $- 14.4$ ($- 30.6$, 5.7)   1.03 (0.99, 1.06)   2.5 ($- 0.6$, 5.8)
    Quartile 3        0.96 (0.78, 1.17)   $- 4.1$ ($- 21.7$, 17.4)   1.02 (0.99, 1.05)   2.1 ($- 0.8$, 5.0)
    Quartile 4        1.01 (0.83, 1.22)   0.8 ($- 16.8$, 22.0)       1.01 (0.98, 1.04)   0.8 ($- 2.3$, 3.9)
  PFOA                                                                                   
   Per IQR increase   1.01 (0.93, 1.1)    1.5 ($- 6.7$, 10.3)        1.01 (0.99, 1.02)   0.6 ($- 0.6$, 1.9)
    Quartile 1        Ref                 Ref                        Ref                 Ref
    Quartile 2        0.96 (0.78, 1.19)   $- 3.9$ ($- 22.3$, 18.8)   0.99 (0.97, 1.02)   $- 0.5$ ($- 3.4$, 2.4)
    Quartile 3        1.02 (0.83, 1.25)   1.6 ($- 17.2$, 24.7)       1.01 (0.98, 1.04)   1.2 ($- 1.9$, 4.4)
    Quartile 4        1.08 (0.86, 1.36)   8.2 ($- 13.9$, 35.9)       1.01 (0.98, 1.04)   0.7 ($- 2.4$, 3.9)
  PFHxS                                                                                  
   Per IQR increase   1.02 (0.96, 1.08)   1.7 ($- 4.4$, 8.1)         1.00 (0.98, 1.01)   $- 0.3$ ($- 1.6$, 1.0)
    Quartile 1        Ref                 Ref                        Ref                 Ref
    Quartile 2        0.98 (0.79, 1.21)   $- 2.1$ ($- 20.7$, 20.8)   0.99 (0.96, 1.02)   $- 1.0$ ($- 4.1$, 2.3)
    Quartile 3        0.92 (0.68, 1.24)   $- 8.2$ ($- 32.1$, 24.2)   1.01 (0.97, 1.05)   1.3 ($- 2.7$, 5.4)
    Quartile 4        1.03 (0.84, 1.27)   3.0 ($- 16.4$, 27.0)       1.02 (0.99, 1.06)   2.5 ($- 1.0$, 6.1)
  PFNA                                                                                   
   Per IQR increase   1.01 (0.95, 1.08)   1.3 ($- 4.8$, 7.7)         1.00 (0.99, 1.01)   $- 0.1$ ($- 1.2$, 0.9)
    Quartile 1        Ref                 Ref                        Ref                 Ref
    Quartile 2        0.97 (0.75, 1.26)   $- 3.1$ ($- 25.4$, 25.9)   1.00 (0.96, 1.04)   $- 0.2$ ($- 3.9$, 3.7)
    Quartile 3        1.01 (0.81, 1.27)   1.4 ($- 19.1$, 27.1)       1.01 (0.97, 1.04)   0.6 ($- 2.9$, 4.3)
    Quartile 4        1.03 (0.82, 1.29)   3.1 ($- 17.7$, 29.0)       1.00 (0.96, 1.03)   $- 0.4$ ($- 3.7$, 3.1)
  PFHpS                                                                                  
   Per IQR increase   1.03 (0.94, 1.13)   3.4 ($- 5.7$, 13.4)        1.00 (0.99, 1.02)   0.1 ($- 1.3$, 1.6)
    Quartile 1        Ref                 Ref                        Ref                 Ref
    Quartile 2        0.95 (0.75, 1.22)   $- 4.6$ ($- 25.4$, 22.1)   0.99 (0.96, 1.03)   $- 0.5$ ($- 3.8$, 2.9)
    Quartile 3        1.01 (0.82, 1.23)   0.6 ($- 18$, 23.5)         1.02 (0.99, 1.05)   1.8 ($- 1.4$, 5.1)
    Quartile 4        1.07 (0.86, 1.33)   7.1 ($- 13.8$, 33.0)       1.00 (0.97, 1.03)   $- 0.2$ ($- 3.4$, 3.1)
  PFDA                                                                                   
   Per IQR increase   0.99 (0.93, 1.05)   $- 1.3$ ($- 7.2$, 4.9)     1.01 (1.00, 1.02)   0.8 ($- 0.4$, 1.9)
    Quartile 1        Ref                 Ref                        Ref                 Ref
    Quartile 2        0.97 (0.79, 1.21)   $- 2.7$ ($- 21.4$, 20.6)   1.01 (0.98, 1.04)   1.0 ($- 2.3$, 4.3)
    Quartile 3        1.00 (0.78, 1.29)   0.4 ($- 21.5$, 28.5)       1.02 (0.98, 1.05)   1.5 ($- 2.3$, 5.4)
    Quartile 4        1.04 (0.83, 1.29)   3.6 ($- 16.7$, 28.8)       1.00 (0.96, 1.03)   $- 0.5$ ($- 3.6$, 2.7)

Note: The model was adjusted for maternal age, parental socio-occupational status, prepregnancy BMI, parity, maternal smoking, and birth year. Study sample indicators (1, 2, 3) were included in the model for continuous exposure and study-specific distributions were used to define PFAS quartiles. Relative percentage difference was calculated as exp(beta). Absolute percentage difference was calculated as $\left\lbrack {\text{exp}\left( \text{beta} \right) - 1} \right\rbrack \times 100\%$. BMI, body mass index; CI, confidence interval; fT4, free thyroxine; IQR, interquartile range; PFAS, perfluoroalkyl substance; PFDA, perfluorodecanoic acid; PFHpS, perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; Ref, reference; TSH, thyroid-stimulating hormone.

Potential Modifying Effects of PFAS on Thyroid Hormones by Gestational Week {#s3.2}
---------------------------------------------------------------------------

In models that allowed gestational-week--specific comparisons of the expected TSH or fT4 values by PFAS exposure, we found that the estimated TSH levels were higher in the top exposure quartile compared with the lower three quartiles for all PFASs from GW5 through GW9 or 10, but this trend became null and reversed after GW10; that is, after GW10, the highest quartile of exposure appeared to be associated with a lower estimated TSH level except for PFOS ([Figure 2](#f2){ref-type="fig"}; see also Table S8). Less apparent differences in trend were found for fT4. There was also a possible reversing of trends for the top quartiles of PFOS, PFHpS, and PFDA that had lower expected fT4 levels prior to GW8 but higher thereafter. These reversing trends (i.e., higher estimated TSH prior to GW10 but lower after) were found for PFOA, PFNA, and PFHpS when we compared the highest to the lowest quartiles (see Figure S2). Trends did not change after simultaneously adjusting for all six PFASs (see Figure S3). In analyses stratified by gestational week ($< 10$, $\geq 10$) at which samples were collected (see Table S9), the highest PFDA quartile was associated with higher TSH levels before GW10 but with lower TSH levels at or after GW10 ($p_{\text{interaction}} = 0.003$). Similar directions were observed for other PFAS and TSH levels, but the 95% CIs of the gestational-week--stratified estimates overlapped and included the null.

###### 

Adjusted (A) TSH and (B) fT4 levels in each gestational week according to binary PFAS exposure. We estimated the expected TSH and fT4 value for each gestational week, comparing the top PFAS quartile to the lower three quartiles while adjusting for maternal age, socio-occupational status, BMI, parity, smoking, and birth year. Study-specific distribution was used to define PFAS quartiles. The model also included interaction terms between PFAS (binary) and gestational week (continuous value and a square term). Whiskers and bars represent 95% CIs in each gestation week. Detailed numeric data for the figure is presented in Table S8. Note: BMI, body mass index; CI, confidence interval; fT4, free thyroxine; PFAS, perfluoroalkyl substance; PFDA, perfluorodecanoic acid; PFHpS, perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; TSH, thyroid-stimulating hormone.

Figure 2A comprises six line graphs plotting TSH (milli international units per liter; y-axis) across gestational age (x-axis) for PFOS, PFOA, PFHxS, PFNA, PHHpS, and PFDA. Figure 2B comprises six line graphs plotting fT4 (picomoles per liter; y-axis) across gestational age (x-axis) for PFOS, PFOA, PFHxS, PFNA, PHHpS, and PFDA.
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PFAS Exposures on Thyroid Status (Based on Gestational-Week--specific Cutoffs) {#s3.3}
------------------------------------------------------------------------------

There were no apparent associations between PFAS exposures and week-specific high or low TSH or fT4 status in the analysis restricted to samples taken before GW10 except for PFDA, which appeared to be correlated with high fT4 levels in the early pregnancy weeks \[$\text{OR} = 1.37$ (95% CI: 1.04, 1.80)\] ([Table 3](#t3){ref-type="table"}). Results were similarly null in the analysis that included all gestational weeks (GW5 to GW19) but only using Study Sample 3 and in the analysis excluding women with thyroid diseases (see Tables S10 and S11).

###### 

High or low week--specific thyroid hormones status according plasma PFAS levels from GW5 to GW10.

Table 3 lists PFAS in the first column; the corresponding number of low TSH, high TSH, low fT4, and high fT4 are listed in the other columns.

  Per IQR increase of each PFAS (ng/mL)   OR and 95% CI[^*b*^](#TF6){ref-type="table-fn"}^,^[^*c*^](#TF7){ref-type="table-fn"}                                           
  --------------------------------------- -------------------------------------------------------------------------------------- ------------------- ------------------- -------------------
  PFOS                                    1.10 (0.70, 1.74)                                                                      0.82 (0.51, 1.31)   0.77 (0.51, 1.17)   1.13 (0.75, 1.68)
  PFOA                                    0.85 (0.59, 1.24)                                                                      0.73 (0.43, 1.25)   0.70 (0.36, 1.39)   1.05 (0.85, 1.31)
  PFHxS                                   1.12 (0.85, 1.47)                                                                      1.15 (0.90, 1.47)   1.07 (0.71, 1.63)   1.18 (0.91, 1.53)
  PFNA                                    0.96 (0.70, 1.32)                                                                      0.81 (0.57, 1.15)   0.87 (0.63, 1.18)   1.09 (0.84, 1.43)
  PFHpS                                   1.31 (0.80, 2.15)                                                                      0.87 (0.53, 1.42)   0.82 (0.53, 1.26)   1.19 (0.74, 1.92)
  PFDA                                    1.15 (0.89, 1.50)                                                                      0.86 (0.61, 1.23)   0.87 (0.60, 1.27)   1.37 (1.04, 1.80)

Note: BMI, body mass index; CI, confidence interval; fT4, free thyroxine; GW, gestational week; IQR, interquartile range; OR, odds ratio; PFAS, perfluoroalkyl substance; PFDA, perfluorodecanoic acid; PFHpS, perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; TSH, thyroid-stimulating hormone.

Low or high TSH and fT4 status were defined using the week-specific lowest 10th or highest 90th percentile.

ORs for each thyroid status were calculated per IQR increase in continuous variables.

Adjusted for maternal age, parental socio-occupational status, BMI, parity, maternal smoking, birth year, and an indicator for study sample.

Discussion {#s4}
==========

In this study, we found no strong association between six types of prenatal PFASs and average changes of TSH or fT4 values in prenatal maternal samples collected from GW5 to GW19 in the DNBC. However, gestational-week--specific analyses suggested a possible crossover trend with top exposure quartiles for several PFASs being associated with higher TSH values up to GW10 and lower values thereafter, and the opposite pattern was observed for fT4 and the highest quartiles of three types of PFAS. These results suggest that PFASs may affect the natural U- or inverted U-shape trends for TSH or fT4 levels in the first trimester of pregnancy with a turning point at GW9 or GW10 ([@c18]; [@c29]). Nevertheless, these gestational-week--specific comparisons in our data were not precise enough to allow us to draw strong conclusions and reevaluation is needed in larger samples. The associations found between PFDA and high fT4 status in early pregnancy could reflect chance findings, but they warrant further investigation.

Even a small disruption in maternal THs may have considerable implications for fetal neurodevelopment ([@c31]), but little is currently known about the possible influence that PFASs may have on these maternal hormones in early gestation. Several pregnancy cohort studies have investigated associations between PFASs and THs in the second or third pregnancy trimesters, but most had relatively small sample sizes with fewer than 400 subjects ([@c7]; [@c24]; [@c52]). Different types of PFASs have been suggested to be either positively or negatively correlated with THs in these studies, with the most consistent finding being a positive association between PFOS and TSH status in the second trimester ([@c7]). One recent study from Boston that analyzed 732 early pregnancy samples collected around GW10 reported that PFOA, PFOS, and PFNA were inversely associated with TSH levels but only among the subset of women with positive thyroid peroxidase antibody and that PFOA, PFHxS, and MeFOSAA were inversely associated with a maternal fT4 index calculated from total T4 and T3 uptake ([@c45]). Our study examined fT4 levels measured via immunoassay instead of using an fT4 index. Although fT4 immunoassay methods could be sensitive to alterations in thyroxine-binding protein in pregnancy ([@c1]; [@c32]), previous studies in the DNBC found that fT4 measures, as well as TSH measures during early pregnancy, were predictive of adverse neurodevelopmental disorders and impaired psychological function in the offspring ([@c2], [@c3]). In addition, our large sample size enabled us to evaluate whether each of the PFAS and TSH or fT4 associations varied by gestational week.

Our findings indicate that PFASs possibly disrupt the normal dynamic TH response in early pregnancy, but whether these minor changes have any developmental implications for the fetus is unknown. Toxicological studies have indicated that PFASs, mainly PFOS and PFOA, have thyroid-disrupting effects that result in hypothyroid function, possibly by regulating hepatic glucuronidation enzymes and deiodinases in the thyroid gland ([@c57]) or reducing HPT axis responsiveness ([@c39]) or binding to transthyretin ([@c48]; [@c54]). Moreover, PFHxS was reported to induce the expression of type 3 deiodinase ([@c51]), which is the physiological inactivator of THs ([@c22]). The dynamic changes in thyroid homeostasis in early pregnancy are mainly due to the surge in human chorionic gonadotropin (hCG) produced by the placenta (i.e., the alpha subunit of the hCG protein, nearly identical to the alpha subunit of TSH), thus TH activities may be altered if PFASs disrupt optimal placenta development and subsequently influence hCG levels ([@c27]; [@c56]). The null findings from our main analysis need to be further elaborated. A possible explanation is that such an analysis does not consider gestational-week--specific variations; for example, if PFASs affect TH levels differently in early versus mid-gestation, this would be expected to result in an overall null association when measures are averaged across all weeks.

Our study has several limitations. First, our analyses did not account for other hemodynamic factors such as albumin and the estimated glomerular filtration rate (eGFR) that could have influenced our results. Albumin is a minor thyroid-binding protein that also binds to PFASs ([@c38]; [@c59]), and the eGFR might affect the renal clearance of PFASs and of iodine---needed for TH production---in pregnancy ([@c38]; [@c49]; [@c59]). Nevertheless, the Boston study showed no evidence for confounding of associations between PFASs and THs in early pregnancy when adjusting for albumin or eGFR in their analyses ([@c45]). Second, thyroid peroxidase antibody status was not measured in the DNBC; thus, we were not able to evaluate possible thyroid-altering effects of PFASs through autoimmune damage ([@c45]; [@c53]). We did not have sufficient numbers to evaluate associations in women with overt or subclinical thyroid dysfunction, and few women in these samples reported thyroid diseases and treatment during early gestations ([@c2], [@c3]). Therefore, the findings of this study are not generalizable to women with thyroid diseases. In addition, we did not have information on iodine intake in the women, and iodine is an essential micronutrient necessary for the synthesis of THs and preventing long-term adverse health outcomes ([@c23]; [@c58]). Main sources of iodine in Denmark are milk, dairy products, iodized salt (used in the commercial production of bread), seafood, and other iodine-containing supplements ([@c47]). In Denmark, the policy of compulsory iodine supplementation was established on a national level in 2000 ([@c10]). Denmark was previously iodine deficient, with regional differences ([@c5]). Thus, we used residency as a proxy for iodine levels in our study population, but the results of the stratified analyses were similar. Future studies should address the potential modifying effect of iodine in the association between PFASs and THs in early pregnancy. We cannot rule out influences from residual uncontrolled confounding, especially dietary habits and lifestyles. Although our analyses were cross sectional, the six evaluated PFASs have long biological half-lives, and thus our measures likely represent cumulative exposures from before pregnancy until the blood samples were taken. Our findings from gestational-week--specific analyses lack statistical precision, especially in early and later weeks when we had fewer samples available. Most of the women who enrolled in the DNBC were healthy and did not have thyroid disorders, and our study did not have sufficient numbers to evaluate associations in women with clinical or subclinical thyroid dysfunction. Finally, TH levels in each gestational week were from different women, and further investigation with repeated samples for each woman is warranted.

In conclusion, we did not find strong evidence to suggest that the evaluated PFASs were associated with overall TSH and fT4 values in the DNBC. Our gestational-week--specific analyses, however, suggested that at the highest PFAS levels, TH levels may be impacted in early pregnancy.
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